Marker Therapeutics FY2025 net loss widens to $12.2 million as grant income falls
Marker Therapeutics reported results for the year ended December 31, 2025, with grant income of $3.5 million, down from $6.6 million in 2024, and a net loss of $12.2 million, up from $10.7 million. The company said its existing cash and cash equivalents will fund operating expenses through the fourth quarter of 2026, assuming no additional grant funds are received.
Key points
- Grant income was $3.5 million for 2025, versus $6.6 million for 2024.
- Net loss was $12.2 million, or $0.79 per share, versus $10.7 million, or $1.19 per share, in 2024.
- Research and development expenses were $11.8 million, versus $13.5 million in 2024; general and administrative expenses were $4.2 million, flat year over year.
- Cash, cash equivalents and restricted cash were $17 million at December 31, 2025, which the company expects to fund operations through the fourth quarter of 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.